Compare Regeneron Pharmaceuticals Inc (REGN) vs Texas Instruments Incorporated (TXN) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

Texas Instruments (TXN) trades at $284.07, showing minimal daily movement. The stock exhibits a mixed technical picture with a bearish moving average signal but oversold RSI levels. Fundamentally, revenue rebounded to $17.68B in 2025 with strong net margins of 29.11%, though recent quarters show inconsistent earnings beats. Analyst consensus remains positive with a $314.27 price target, supported by ongoing dividend payments and leadership transition news.

Outlook balances solid profitability and AI-driven demand potential against high valuation multiples and rising debt levels. Key opportunities include margin expansion from 300mm capacity and data center growth, while risks involve competitive pressures and execution of the new CFO. The stock presents a hold case for dividend investors but requires monitoring for sustained earnings improvement.